ICON plc (ICLR)

Healthcare
Diagnostics & Research
Ireland
Yahoo Finance  •  Trading View  •  Company site
Price
$144.55
▼ -10.02 (-6.48%)
Market Cap
$11,241,961,472
Shares: 76,359,932
P/E
N/A
P/B: N/A
ROE
N/A
Current Ratio: N/A
Fundamentals Score
17 (NEGATIVE)

Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Headquarters: South County Business Park, Dublin, D18 X5R3, Ireland  |  Employees: 39800  |  Website: iconplc.com
Key Contacts
IR / Phone: 353 1 291 2000
Exchange: NMS
Industry: Diagnostics & Research
Quick Financial Snapshot
RevenueN/A
Net IncomeN/A
Free Cash FlowN/A
Book Value / ShareN/A

Balance Sheet & Liquidity

Total LiabilitiesN/A
Total EquityN/A
Debt / EquityN/A
Current RatioN/A
Interest CoverageN/A
Working CapitalN/A

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)N/A
Industry P/EN/A
Forward P/E10.98
P/BN/A
Price / SalesN/A
P / FCFN/A
EV / EBITDAN/A
Graham NumberN/A
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROIC N/A
Asset Turnover N/A

Automated Fundamental Signals (Score: 17)

Passed
  • Price CAGR 6.75%
Failed
  • Positive Free Cash Flow
  • DCF valuation (undefined)

Price Chart (Candlestick)

Technical Analysis (Score: 75)

RSI (14)27.92
SMA 50180.98
SMA 200166.08
MACD-8.68
Signal BULLISH
RSI 27.9, SMA trend bullish, momentum -24.3%.

Governance & Management

Governance scores: Audit: N/A | Board: N/A | Compensation: N/A | Shareholder Rights: N/A
Executive Team
NameTitle
Dr. John Climax Ph.D. Founder & Independent Non-Executive Director (1953)
Mr. Nigel Clerkin A.C.A. Chief Financial Officer (1974)
Mr. Barry Balfe CEO & Director (1979)
Mr. Thomas N. O'Leary Chief Information Officer (—)
Mr. Diarmaid Cunningham Chief Administrative Officer, General Counsel & Company Secretary (1975)
Ms. Niamh Murphy Director of Corporate Communications (—)
Mr. David Green Vice President of Marketing (—)
Mr. Joe Cronin Chief Human Resources Officer (—)
Governance data last updated: N/A

Latest News

No news available for this company.

← Back